Skip to main content

Table 1 Study demographics

From: Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies

  

Placebo

AZD9164

Total

GMAD, healthy subjects

 

n = 9

400 μg n = 6

1000 μg n = 6

2800 μg n = 6

n = 27

Age (yrs)

Mean

26

21

23

22

23

SD

6

1

3

2

4

aBMI (kg/m2)

Mean

23.1

23.4

21.7

21.6

22.5

SD

1.7

1.8

2.2

1.1

1.8

aWeight (kg)

Mean

73.8

80.3

70.7

70.0

73.7

 

SD

6.8

8.1

7.4

4.7

7.6

JMAD, healthy subjects

 

n = 6

400 μg n = 6

1000 μg n = 6

n = 18

Age (years)

Mean

Mean 29.8

29.0

27.5

28.8

SD

4.9

4.0

3.4

4.0

aBMI (kg/m2)

Mean

21.0

20.7

20.6

20.8

 

SD

1.2

2.3

1.4

1.6

aWeight (kg)

Mean

61.3

63.6

61.4

62.1

 

SD

4.3

7.7

5.5

5.8

GMAD, COPD patients

 

n = 1

1000 μg n = 3

n = 4

Age (yrs)

Mean

71

64

66

 

SD

NC

7

6

aBMI (kg/m2)

Mean

23.0

27.8

 

26.6

 

SD

NC

4.0

 

4.0

aWeight (kg)

Mean

77.1

73.9

74.7

 

SD

NC

8.1

6.8

bFEV1 (L)

Mean

1.62

1.48

1.52

 

SD

NC

0.53

0.43

bFEV1 (% predicted)

Mean

48.80

64.63

60.67

 

SD

NC

17.82

16.57

bFEV1/FVC (%)

Mean

31.95

49.45

45.08

 

SD

NC

5.66

9.90

Smoking history (%)

Current

1 (100)

2 (67)

 

3 (75)

 

Former

0 (0)

 

1 (33)

 

1 (25)

Years since diagnosis

Mean

5

 

10

 

9

 

SD

NC

 

9

 

8

  1. aAt enrolment.
  2. bFEV1 and FVC measurements were made after inhalation of Atrovent® (post-bronchodilator).
  3. BMI Body mass index, NC Not calculable.